Carsinosa is developing a first-in-class oral small molecule drug to be used in the treatment of a range of difficult-to-treat cancers including metastatic prostate cancer, breast cancer, ovarian cancer and colon cancer. This is based on research initiated at University of Queensland’s Frazer Institute and progressed in collaboration with Queensland Emory Drug Discovery Initiative (QEDDI). The CUREator program will support the optimisation of candidates to allow for in vivo validation.